RxDoctor Payments Data

Tamim Nazif, MD

Cardiovascular Disease · New York, NYNPI 1942323944

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Edwards Lifesciences at 54.1% of the total. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$161,877in general payments, 2019–2025

Across 495 payments — averaging $327.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$88K
  • Boston Scientific$29K
  • Biotrace Medical, Inc.$14K
  • Baylis Medical Company Inc$9K
  • Medtronic$8K
  • Shockwave Medical, Inc$4K
  • plus $11K from 23 others
$2,085,172in research payments, 2019–2025

Across 152 payments — averaging $13,718 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$1.1M
  • Boston Scientific$659K
  • Medtronic$259K
  • Abbott$36K

What the payments were for

  • Consulting fees$76,26347%
  • Speaking & faculty fees$16,79910%
  • Travel & lodging$52,13732%
  • Food & beverage$16,67710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$161,877 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$176,189
Medicare patients
285
Services billed
743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate16$112
Atorvastatin Calcium12$84

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →